Fig. 7

Influence of EID3 on tumorigenesis of GCSCs in vivo. A Role of EID3 in tumor growth in mice. GCSCs (cisplatin-induced, doxorubicin-induced, X-ray-induced or sorted GCSCs), transfected with EID3-siRNA, EID3 rescue or siRNA control, were injected into nude mice. The tumor volume in mice was measured every week for a 7-week period. B Tumor sizes of mice with different treatments. C Tumor weights of mice injected with GCSCs transfected with EID3-siRNA, EID3 rescue or siRNA control. D Protein levels of EID3, β-catenin, NAMPT and stemness signatures in the solid tumors of the mice injected with the EID3-silenced or the EID3-rescued GCSCs (cisplatin-induced, doxorubicin-induced, X-ray-induced or sorted GCSCs). The proteins were examined with Western blot. Β-tubulin was used as a control. E The relationship between the EID3 expression level and the histological grades of gastric cancer patients. The EID3 expression level and the pathological stages of gastric cancer patients were characterized using The Cancer Genome Atlas (TCGA). Stage 1, cancer limited to single cancer tissue (n = 18); Stage 2, partially infiltrating cancer (n = 123); Stage 3, cancer with lymphatic metastasis (n = 169). F The relationship between the EID3 expression level and the histological grades of gastric cancer patients. Grade 1, well differentiated (low grade); Grade 2, moderately differentiated (intermediate grade); Grade 3, poorly differentiated (high grade). G Kaplan–Meier analysis of gastric cancer patients with high and low expression level of EID3. EID3-low group, n = 282; EID3-high group, n = 349; HR, hazard ratio. In all panels, the statistical significance of differences between treatments was indicated with asterisks (*p < 0.05; **p < 0.01)